/
Oncology
Solid Malignancies
32
Pipeline Programs↗
25
Active Trials↗
44
Companies Involved↗
Solid Malignancies is a moderately active landscape with 32 programs across 44 companies. The most active players are Taizhou Mabtech Pharmaceutical Co.,Ltd, Carrick Therapeutics Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 112
Phase 212
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
68%
Small molecule
21 of 31 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.
Analysis
Trial Status
129
clinical trials
Completed70 · 54%
Terminated23 · 18%
Recruiting17 · 13%
Active, not recruiting7 · 5%
Unknown status6 · 5%
Withdrawn3 · 2%
Other3 · 2%
Clinical Trials
Trial Activity
129 trials
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)